Precarious Elderly Patient Supported For Cancer Impact on Quality Of Life of a Domotic And Remote Assistance Approach for Elderly Patients Supported For Locally Advanced or Metastatic Cancer, Socially Isolated

Time to failure of first line of treatment

Time between inclusion and treatment failure, whatever the cause

Time frame: From date of inclusion until treatment failure, up to 6 months

First line of treatment toxicity at the end

Measured by Toxicity scale NCI-CTCAE (National Cancer Institute - Common Terminology Criteria for Adverse Events, version 4.0).

Time frame: 12 months

Assessment of the number of chemotherapies received by patient compared to the number of prescribed chemotherapies

Treatment compliance

Time frame: 12 months

Assessment of the patient dependency level determined by evaluating the Daily living activities (ADL) with the Katz scale

Time frame: 3 months and 6 months

Assessment of the patient dependency level determined by evaluating the- instrumental activities across Lawton scale

Time frame: 3 months and 6 months

Nutritional assessment at 3 months and 6 months

Body mass index (BMI) is the ratio of weight to height in cm squared.

Time frame: 3 months and 6 months

Functional assessment at 3 months and 6 months

The unipodal station is to stand on one foot without aid. A unipodal station less than 5 seconds indicating a high risk of falls (46).

Time frame: 3 months and 6 months

Overall Survival defined as the time between chemotherapy start and death

will be assessed at 6 months and 1 year

Time frame: up to 12 months

Progression free Survival defined as the time between treatment start and the date of first documented progression or death, whatever the cause.

Time to progression is the time elapsed between the date of treatment start and the occurrence of progression or relapse if a response was observed (response or stabilization). A patient who has not progressed or who did not die at the limit of 1 year will have its censored survival time when tumor enough last evaluation conducted by the deadline of 1 year . The progress will then be defined according to the criteria RECIST1.1 . In case of death , it will be identified if it is related to tumor progression , toxicity or complication of treatment or another cause (non-specific death).

Time frame: up to 12 months

Social isolation

Social isolation will be measured by the m -MOS questionnaire. A result \< 80% is recognized as the consensus inferior value below which patients are socially isolated position

Time frame: 12 months

Measure of the "global health score" to assess the quality of life at first line of treatment

Time frame: 3 months and 6 months